Full-Life Technologies is a dynamic, fully integrated global radiopharmaceutical company with operations spanning Belgium, Germany, and China. Since its inception in 2021, the company aims to revolutionize the radiotherapeutics industry by owning the entire value chain from research and development to production and commercialization.
Driven by a team of adept entrepreneurs and scientists with extensive expertise in life sciences and clinical development, Full-Life Technologies addresses major challenges in the field through cutting-edge research focused on future therapies.
Headquartered in Belgium, the company recently secured a significant financial boost, closing a $47.30M Series B funding round on 03 January 2024. This investment was led by prominent investors such as Chengwei Capital, Sky9 Capital, and Sequoia Capital China, among others, signaling strong confidence in their growth trajectory.